Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody drug conjugates (ADCs) are a significant advancement in cancer therapy, comprising an antibody, a cytotoxic payload, and a linker.
• Several ADCs are FDA-approved for hematologic malignancies and solid tumors, with this review focusing on the latter.
• The efficacy of ADCs relies on specific antigen targeting, linker stability, and payload delivery following cellular internalization and lysosomal processing.

Purpose of the Study:

• To review the design evolution of ADCs for solid tumors.
• To examine the impact of spatial and temporal intratumoral heterogeneity on ADC therapy efficacy.
• To discuss strategies for overcoming heterogeneity to improve durable responses in solid malignancies.

Main Methods:

• Review of existing literature on ADC design and clinical applications in solid tumors.
• Analysis of factors contributing to ADC efficacy, including antigen selection, linker chemistry, and payload characteristics.
• Exploration of preclinical and clinical strategies to address intratumoral heterogeneity.

Main Results:

• The design of ADCs for solid tumors has evolved successfully, encompassing antigen targeting, linker technology, and payload optimization.
• Intratumoral heterogeneity is a key limitation to achieving durable efficacy with current ADC therapies.
• Strategies such as enhanced clinical sample characterization, refined ADC design, and combinatorial approaches are being investigated.

Conclusions:

• Overcoming intratumoral heterogeneity is crucial for enhancing the durable efficacy of antibody drug conjugates in solid tumors.
• Continued research into ADC design, patient selection, and combination therapies holds promise for improving treatment outcomes.
• Future efforts aim to optimize ADC therapy to overcome heterogeneity challenges and improve patient responses in solid malignancies.